文献速递脑血管病

Lp-PLA2活性与基因型指导的双联抗血小板治疗在轻型卒中或短暂性脑缺血发作中的作用

Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack.
PubMed 文献 · Stroke · 2026-01-13

本研究基于CHANCE-2试验,纳入5919例携带CYP2C19功能缺失等位基因的轻型卒中或短暂性脑缺血发作患者,按基线Lp-PLA2活性中位数188.4 nmol/min/mL分层,评估替格瑞洛-阿司匹林与氯吡格雷-阿司匹林的疗效和安全性。结果显示,在低Lp-PLA2活性组,替格瑞洛-阿司匹林降低90天卒中复发风险(5.4% vs 7.4%;调整HR 0.72 [95%CI 0.54-0.97]),高活性组无显著差异(6.9% vs 8.2%;调整HR 0.84 [95%CI 0.65-1.09]),交互作用P=0.45;出血风险无差异。结论认为Lp-PLA2活性未显著改变双联抗血小板治疗的疗效或安全性。

要点

  • 在低Lp-PLA2活性患者中,替格瑞洛-阿司匹林较氯吡格雷-阿司匹林降低90天卒中复发风险。
  • 高Lp-PLA2活性患者中两种治疗无显著差异,交互作用P=0.45。
  • 出血风险在不同Lp-PLA2活性水平间无差异。

核心结论

  • 在携带CYP2C19功能缺失等位基因的轻型卒中或TIA患者中,Lp-PLA2活性升高未显著改变双联抗血小板治疗的疗效或安全性。

研究设计与样本

  • 基于CHANCE-2试验的亚组研究,纳入5919例有基线Lp-PLA2活性数据的患者,按中位数188.4 nmol/min/mL分层。
  • CHANCE-2试验随机分配6412例携带CYP2C19功能缺失等位基因的轻型卒中或TIA患者接受替格瑞洛-阿司匹林或氯吡格雷-阿司匹林。

主要发现

  • 低Lp-PLA2活性组:替格瑞洛-阿司匹林vs氯吡格雷-阿司匹林90天卒中复发风险5.4% vs 7.4%,调整HR 0.72(95%CI 0.54-0.97)。
  • 高Lp-PLA2活性组:卒中复发风险6.9% vs 8.2%,调整HR 0.84(95%CI 0.65-1.09)。
  • 治疗×Lp-PLA2活性对卒中复发的交互作用P=0.45。
  • 替格瑞洛-阿司匹林相关出血风险在不同Lp-PLA2活性水平间无差异。

临床怎么用

  • 对于携带CYP2C19功能缺失等位基因的轻型卒中或TIA患者,Lp-PLA2活性不宜作为选择替格瑞洛-阿司匹林或氯吡格雷-阿司匹林的依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lp-PLA2 (lipoprotein-associated phospholipase A2) is a sensitive biomarker of vascular inflammation and atherosclerosis. This study evaluated the influence of Lp-PLA2 activity on the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin among patients with minor stroke or transient ischemic attack carrying CYP2C19 loss-of-function alleles. METHODS: The CHANCE-2 trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events-II) randomized 6412 patients with minor stroke or transient ischemic attack carrying CYP2C19 loss-of-function alleles to receive ticagrelor-aspirin or clopidogrel-aspirin. This subgroup study included patients with available baseline Lp-PLA2 activity measurements, stratified by the median value of 188.4 nmol/min per milliliter. The primary efficacy and safety outcomes were stroke recurrence and severe or moderate bleeding events within 90 days. Associations between treatment and outcomes were assessed using multivariable Cox proportional hazards models, adjusting for a history of hyperlipidemia. RESULTS: A total of 5919 patients were included (mean age, 64.4 years; 33.9% female). Among patients with low Lp-PLA2 activity, ticagrelor-aspirin reduced the 90-day risk of recurrent stroke compared with clopidogrel-aspirin (5.4% versus 7.4%; adjusted hazard ratio, 0.72 [95% CI, 0.54-0.97]). In patients with high Lp-PLA2 activity, no significant difference was observed (6.9% versus 8.2%; adjusted hazard ratio, 0.84 [95% CI, 0.65-1.09]). The P value was 0.45 for the treatment × Lp-PLA2 activity interaction effect on stroke recurrence. The risk of bleeding associated with ticagrelor-aspirin did not differ across Lp-PLA2 activity levels. CONCLUSIONS: In patients with minor stroke or transient ischemic attack carrying CYP2C19 loss-of-function alleles, elevated Lp-PLA2 activity did not significantly modify the efficacy or safety of dual antiplatelet therapy. Further research is needed to clarify the potential role of Lp-PLA2 in guiding individualized treatment decisions. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04078737.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Lin J, Zhou H, Wang Y, et al. Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack. Stroke. 2026. PMID: 41527826. doi:10.1161/STROKEAHA.125.052954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。